BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 38894724)

  • 21. The effectiveness of blinatumomab in clearing measurable residual disease in pediatric B-cell acute lymphoblastic leukemia patients detected by next-generation sequencing.
    Gu M; Xia Y; Zhang J; Tang Y; Xu W; Song H; Xu X
    Cancer Med; 2023 Dec; 12(24):21978-21984. PubMed ID: 38063317
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Mutational spectrum and its prognostic significance in childhood acute lymphoblastic leukemia based on next-generation sequencing technology].
    Zheng YZ; Zheng H; Chen ZS; Hua XL; Le SH; Li J; Hu JD
    Zhonghua Xue Ye Xue Za Zhi; 2022 Jan; 43(1):19-25. PubMed ID: 35231988
    [No Abstract]   [Full Text] [Related]  

  • 23. Clinical applications of next-generation sequencing in colorectal cancers.
    Kim TM; Lee SH; Chung YJ
    World J Gastroenterol; 2013 Oct; 19(40):6784-93. PubMed ID: 24187453
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Integration of Next-Generation Sequencing to Treat Acute Lymphoblastic Leukemia with Targetable Lesions: The St. Jude Children's Research Hospital Approach.
    Inaba H; Azzato EM; Mullighan CG
    Front Pediatr; 2017; 5():258. PubMed ID: 29255701
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Difference in gene mutation profile in patients with refractory/relapsed versus newly diagnosed acute myeloid leukemia based on targeted next-generation sequencing.
    Wang M; Wang R; Wang H; Chen C; Qin J; Gao X; Yu L
    Leuk Lymphoma; 2021 Oct; 62(10):2416-2427. PubMed ID: 33913388
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Detection of recurrent, rare, and novel gene fusions in patients with acute leukemia using next-generation sequencing approaches.
    Kim B; Kim E; Lee ST; Cheong JW; Lyu CJ; Min YH; Choi JR
    Hematol Oncol; 2020 Feb; 38(1):82-88. PubMed ID: 31875988
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The RAS-signaling-pathway-mutation-related prognosis in B-cell acute lymphoblastic leukemia: A report from South China children's leukemia group.
    Li X; Lin S; Liao N; Mai H; Long X; Liu L; Wu B; Chen Q; Kong Q; Kong X; Liu L; Qin J; Fang J; Zhou D
    Hematol Oncol; 2024 May; 42(3):e3265. PubMed ID: 38564328
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical application of next-generation sequencing-based monitoring of minimal residual disease in childhood acute lymphoblastic leukemia.
    Mai H; Li Q; Wang G; Wang Y; Liu S; Tang X; Chen F; Zhou G; Liu Y; Li T; Wang L; Wang C; Wen F; Liu S
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):3259-3266. PubMed ID: 35918464
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relapsed/Refractory T- Acute Lymphoblastic Leukemia - Current Options and Future Directions.
    Jeha S
    Indian J Pediatr; 2024 Feb; 91(2):168-175. PubMed ID: 37642889
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse.
    Short NJ; Kantarjian H; Ravandi F; Konopleva M; Jain N; Kanagal-Shamanna R; Patel KP; Macaron W; Kadia TM; Wang S; Jorgensen JL; Khoury JD; Yilmaz M; Kebriaei P; Takahashi K; Garcia-Manero G; Daver N; Post SM; Huang X; Kornblau SM; Pelletier S; Flores W; Matthews J; Garris R; Jabbour E
    Blood Adv; 2022 Jul; 6(13):4006-4014. PubMed ID: 35533262
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design and Validation of a Custom Next-Generation Sequencing Panel in Pediatric Acute Lymphoblastic Leukemia.
    Gil JV; Such E; Sargas C; Simarro J; Miralles A; Pérez G; de Juan I; Palanca S; Avetisyan G; Santiago M; Fuentes C; Fernández JM; Vicente AI; Romero S; Llop M; Barragán E
    Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901871
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New Challenges in Targeting Signaling Pathways in Acute Lymphoblastic Leukemia by NGS Approaches: An Update.
    Montaño A; Forero-Castro M; Marchena-Mendoza D; Benito R; Hernández-Rivas JM
    Cancers (Basel); 2018 Apr; 10(4):. PubMed ID: 29642462
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Uncovering the Genomic Landscape in Newly Diagnosed and Relapsed Pediatric Cytogenetically Normal FLT3-ITD AML.
    Buelow DR; Pounds SB; Wang YD; Shi L; Li Y; Finkelstein D; Shurtleff S; Neale G; Inaba H; Ribeiro RC; Palumbo R; Garrison D; Orwick SJ; Blachly JS; Kroll K; Byrd JC; Gruber TA; Rubnitz JE; Baker SD
    Clin Transl Sci; 2019 Nov; 12(6):641-647. PubMed ID: 31350825
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Proteomics in Childhood Acute Lymphoblastic Leukemia: Challenges and Opportunities.
    Kourti M; Aivaliotis M; Hatzipantelis E
    Diagnostics (Basel); 2023 Aug; 13(17):. PubMed ID: 37685286
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is Next-Generation Sequencing the way to go for Residual Disease Monitoring in Acute Lymphoblastic Leukemia?
    Kotrova M; Trka J; Kneba M; Brüggemann M
    Mol Diagn Ther; 2017 Oct; 21(5):481-492. PubMed ID: 28452038
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical Next Generation Sequencing for Precision Medicine in Cancer.
    Dong L; Wang W; Li A; Kansal R; Chen Y; Chen H; Li X
    Curr Genomics; 2015 Aug; 16(4):253-63. PubMed ID: 27006629
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of childhood acute lymphoblastic leukemia after the first relapse: curative strategies.
    Uderzo C; Dini G; Locatelli F; Miniero R; Tamaro P
    Haematologica; 2000 Nov; 85(11 Suppl):47-53. PubMed ID: 11268324
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A review of CD19-targeted immunotherapies for relapsed or refractory acute lymphoblastic leukemia.
    DasGupta RK; Marini BL; Rudoni J; Perissinotti AJ
    J Oncol Pharm Pract; 2018 Sep; 24(6):453-467. PubMed ID: 28583018
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Insights of Acute Lymphoblastic Leukemia with Development of Genomic Investigation.
    Xu H; Shu Y
    Methods Mol Biol; 2018; 1754():387-413. PubMed ID: 29536454
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genomic characterization of relapsed acute myeloid leukemia reveals novel putative therapeutic targets.
    Stratmann S; Yones SA; Mayrhofer M; Norgren N; Skaftason A; Sun J; Smolinska K; Komorowski J; Herlin MK; Sundström C; Eriksson A; Höglund M; Palle J; Abrahamsson J; Jahnukainen K; Munthe-Kaas MC; Zeller B; Tamm KP; Cavelier L; Holmfeldt L
    Blood Adv; 2021 Feb; 5(3):900-912. PubMed ID: 33560403
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.